Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
Repository of the University of Ljubljana
Open Science Slovenia
Open Science
DiKUL
slv
|
eng
Search
Advanced
New in RUL
About RUL
In numbers
Help
Sign in
Details
Preconception use of GLP-1 and GLP-1/GIP receptor agonists for obesity treatment
ID
Koceva, Andrijana
(
Author
),
ID
Janež, Andrej
(
Author
),
ID
Jensterle Sever, Mojca
(
Author
)
PDF - Presentation file,
Download
(1,45 MB)
MD5: ACC03FAF4F6A7F57B7A1F865761D2EC8
URL - Source URL, Visit
https://www.sciencedirect.com/science/article/abs/pii/S1521690X25000715
Image galllery
Abstract
Obesity is rising among women of reproductive age and significantly contributes to subfertility. If conception occurs, maternal obesity is associated with increased risks for both maternal and neonatal complications, with potential long-term effects on the offspring's health. Current clinical guidelines emphasize the importance of preconception weight optimization in women with obesity to reduce maternal and fetal risks. Amid the rising use of incretin-based anti-obesity medications, particularly among young women, their potential role in preconception care is receiving growing clinical and research interest. With unplanned pregnancies remaining common, incidental exposure during early pregnancy is becoming more likely. In parallel, there is increasing interest in the potential of these agents to support preconception weight loss and enhance fertility outcomes in women with obesity. This narrative review examines the current human evidence on GLP-1 and dual GLP-1/GIP receptor agonists approved for obesity treatment, focusing on their potential role in preconception care and addressing key safety considerations and challenges related to their use during the preconception period, as well as inadvertent exposure in early pregnancy.
Language:
English
Keywords:
GLP-1 receptor agonist
,
GLP-1/GIP receptor agonist
,
preconception care
,
liraglutide
,
semaglutide
,
tirzepatide
Work type:
Article
Typology:
1.02 - Review Article
Organization:
MF - Faculty of Medicine
Publication status:
Published
Publication version:
Version of Record
Year:
2025
Number of pages:
10 str.
Numbering:
Vol. 39, iss. 6, art. 102038
PID:
20.500.12556/RUL-182728
UDC:
616.4
ISSN on article:
1521-690X
DOI:
10.1016/j.beem.2025.102038
COBISS.SI-ID:
250744067
Publication date in RUL:
21.05.2026
Views:
263
Downloads:
231
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Copy citation
Share:
Record is a part of a journal
Title:
Baillière's best practice & research. Clinical endocrinology and metabolism
Shortened title:
Baillière's best pract. res. Clin. endocrinol. metab.
Publisher:
Elsevier
ISSN:
1521-690X
COBISS.SI-ID:
2071060
Licences
License:
CC BY 4.0, Creative Commons Attribution 4.0 International
Link:
http://creativecommons.org/licenses/by/4.0/
Description:
This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Secondary language
Language:
Slovenian
Keywords:
agonist receptorja GLP-1
,
agonist receptorja GLP-1/GIP
,
predzanositvena oskrba
Similar documents
Similar works from RUL:
Similar works from other Slovenian collections:
Back